GSK Has High Hopes For COPD Vaccine
Phase II Data This Year
Executive Summary
By combining its expertise in respiratory and vaccines, the UK drugs giant could have a potential blockbuster for chronic obstructive pulmonary disease, which is expected to become the third leading cause of death worldwide by the end of the decade.